Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Completed · Phase 3

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).

Key facts

Study ID

NCT00104013

Run by

Sanofi

People needed

1455

Starts

2003-11-01

Expected to finish

2007-11-01

Last updated by the study team

2008-08-21

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria
• Mild to moderate degree of severity of dementia as assessed by the Mini-Mental Status Examination score of 16 to 26 (inclusive)
• Potential participant may be treated with conventional Alzheimer's disease therapy and must be on a stable dose for at least 6 months prior to the randomization and during the entire study period
• Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility
• Mother tongue is English, Spanish or French (oral and written fluency)
• Signed informed consent from potential participant or legal representative and identified caregiver

You may not qualify if…

• Potential participant with any other cause of dementia.
• Potential participant with serious health problems other than Alzheimer's disease
• Use of an investigational drug within two months prior to randomization or during this study

Where it is running

• Neurological Physicians of Arizona, Inc. — Mesa, Arizona, United States
• Pivotal Research Centers — Mesa, Arizona, United States
• Pivotal Research Centers — Peoria, Arizona, United States
• Northwest NeuroSpecialists — Tucson, Arizona, United States
• Optimum Health Services — Oceanside, California, United States
• Anderson Clinical Research — Redlands, California, United States
• Univ. of CT Health Center — Farmington, Connecticut, United States
• CNS Healthcare — Jacksonville, Florida, United States
• Mayo Clinic — Jacksonville, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Memory Disorder Center — Pompano Beach, Florida, United States
• Neurological Center — Fort Wayne, Indiana, United States
• Vince and Associates Clinical Research — Overland Park, Kansas, United States
• Hartford Research Group — Florence, Kentucky, United States
• Lexington Clinic — Lexington, Kentucky, United States
• LSUHSC Geriatric Psychiatry — New Orleans, Louisiana, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Synergy Medical — Saginaw, Michigan, United States
• University Medical Center, Dept. of Psychiatry Clinical Trials — Jackson, Mississippi, United States
• Radiant Research, Inc. — St Louis, Missouri, United States
• Center For Emotional Fitness — Moorestown, New Jersey, United States
• Ubhc/Umdnj667 — Piscataway, New Jersey, United States
• The Ohio State University — Columbus, Ohio, United States
• The Clinical Trial Center — Jenkintown, Pennsylvania, United States
• Radiant Research — Greer, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.